Labiotech

CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off?
Source: Labiotech Published on 2023-10-04
Five impactful biotech companies to know in New York
Source: Labiotech Published on 2023-10-03
Protecting privacy across borders: Is strategic outsourcing the answer to data protection compliance in clinical research?
Source: Labiotech Published on 2023-10-03
PIPEs in biotech fundraising: is this growing trend fueled by economic uncertainty here to stay?
Source: Labiotech Published on 2023-10-02
Illumina: DNA giant in troubled waters
Source: Labiotech Published on 2023-09-29
Beyond Biotech podcast 65 – Disease X and pandemic preparedness
Source: Labiotech Published on 2023-09-29
Obesity drug success sparks biotech buying spree
Source: Labiotech Published on 2023-09-28
Tackling the skilled labor shortage in biopharma manufacturing
Source: Labiotech Published on 2023-09-27
Eight anti-aging startups on a mission to extend lives
Source: Labiotech Published on 2023-09-26
Unlocking the potential of cell and gene therapies
Source: Labiotech Published on 2023-09-26
Base editing hits the clinic in the U.S.
Source: Labiotech Published on 2023-09-25
U.S. approval for psychedelic drug MDMA nears after success in clinic
Source: Labiotech Published on 2023-09-22
Beyond Biotech podcast 64 – Precision immuno-oncology therapies
Source: Labiotech Published on 2023-09-22
Recent advancements in prostate cancer research over the past year
Source: Labiotech Published on 2023-09-21
The next frontier in genomic technologies for rare diseases
Source: Labiotech Published on 2023-09-20